Novavax Inc (NVAX) - Financial and Strategic SWOT Analysis Review

May 2021 | 53 pages | ID: N897C770ADBEN
GlobalData

Abstracts

Novavax Inc (NVAX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Novavax Inc (Novavax) discovers, develops and commercializes vaccines to prevent a wide range of infectious diseases. The company develops vaccines using its proprietary recombinant nanoparticle vaccine technology and matrix technology. Its pipeline products includes NVX-CoV2373 for coronavirus, NanoFlu for seasonal influenza, ResVax for respiratory syncytial syndrome and vaccines indicated against ebola virus, middle east respiratory syndrome and severe acute respiratory syndrome. The company operates research and manufacturing facilities in Gaithersburg, Maryland; Uppsala, Sweden; and Bohumil, Czech Republic. Novavax is headquartered in Gaithersburg, Maryland, the US.

Novavax Inc Key Recent Developments

May 10,2021: Novavax Reports First Quarter 2021 Financial Results and Operational Highlights
Apr 13,2021: Novavax Announces Leadership Updates
Apr 08,2021: Novavax to Participate in Fireside Chat at Goldman Sachs Virtual Conference
Mar 30,2021: US study reveals Pfizer-BioNTech and Moderna Covid-19 vaccines reduce infection risk
Mar 01,2021: Novavax reports fourth quarter and full year 2020 financial results and operational highlights

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Novavax Inc - Key Facts
Novavax Inc - Key Employees
Novavax Inc - Key Employee Biographies
Novavax Inc - Major Products and Services
Novavax Inc - History
Novavax Inc - Company Statement
Novavax Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture

SECTION 2 – COMPANY ANALYSIS

Company Overview
Novavax Inc - Business Description
Other Break-up: Government Contracts
Performance
Other Break-up: Grants and Other
Performance
R&D Overview
Novavax Inc - SWOT Analysis
SWOT Analysis - Overview
Novavax Inc - Strengths
Novavax Inc - Weaknesses
Novavax Inc - Opportunities
Novavax Inc - Threats
Novavax Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Novavax Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Novavax Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Novavax Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

May 10, 2021: Novavax Reports First Quarter 2021 Financial Results and Operational Highlights
Apr 13, 2021: Novavax Announces Leadership Updates
Apr 08, 2021: Novavax to Participate in Fireside Chat at Goldman Sachs Virtual Conference
Mar 30, 2021: US study reveals Pfizer-BioNTech and Moderna Covid-19 vaccines reduce infection risk
Mar 01, 2021: Novavax reports fourth quarter and full year 2020 financial results and operational highlights
Feb 16, 2021: Novavax, SK Bioscience expand Covid-19 vaccine manufacturing deal
Feb 16, 2021: Novavax to Host Conference Call to Discuss Fourth Quarter Financial Results and Operational Highlights on March 1, 2021
Jan 22, 2021: Novavax names Madelyn Caltabiano senior vice president, global program management
Jan 15, 2021: Regulatory expert Henrietta Ukwu, M.D. appointed Novavax Chief Regulatory and Quality Officer
Dec 21, 2020: Biopharma Executive Rick Crowley joins Novavax as Chief Operations Officer

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Novavax Inc, Key Facts
Novavax Inc, Key Employees
Novavax Inc, Key Employee Biographies
Novavax Inc, Major Products and Services
Novavax Inc, History
Novavax Inc, Subsidiaries
Novavax Inc, Joint Venture
Novavax Inc, Key Competitors
Novavax Inc, Ratios based on current share price
Novavax Inc, Annual Ratios
Novavax Inc, Annual Ratios (Cont...1)
Novavax Inc, Interim Ratios
Novavax Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Novavax Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Novavax Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Novavax Inc, Performance Chart (2016 - 2020)
Novavax Inc, Ratio Charts
Novavax Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Novavax Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021